Improving the delivery of 5-aminolaevulinic acid in photodynamic therapy (PDT): synthesis and biological studies of novel peptide prodrugs
Improving the delivery of 5-aminolaevulinic acid in photodynamic therapy (PDT): synthesis and biological studies of novel peptide prodrugs
批准号:
BB/D011329/1
负责人:
Alexander MacRobert
金额:
$27.25万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2006
资助国家:
英国
项目状态:
已结题
起止时间:
2006 至 --
中文摘要
该项目的主要目的是设计用于光动力疗法(PDT)的新药,PDT是一种可用于摧毁癌症和杀死传染性细菌的治疗方法。PDT的主要特点是它使用一种被称为“光敏剂”的光激活药物。当光激活药物时,这导致对肿瘤细胞或细菌的毒性作用,导致肿瘤的破坏或细菌感染的愈合。实际上,光“打开”药物,但仅在暴露于光的区域。我们建议研究一种基于5-氨基乙酰丙酸(ALA)的新型药物。这是一种天然化合物,存在于许多细胞中,但通常水平很低。然而,如果细胞或细菌暴露于高浓度的ALA,则产生光敏剂(卟啉),其吸收从红色到蓝色的宽范围的光,因此可以用于PDT治疗。例如,皮肤肿瘤可以通过首先用含有ALA的洗剂覆盖肿瘤,然后放置几个小时来治疗。在ALA渗入肿瘤后,光照几分钟以杀死肿瘤细胞。或者,可以注射或口服ALA溶液以治疗体内的肿瘤,其中可以使用内窥镜将光引导到肿瘤上。然而,使用ALA的一个主要问题是它不能迅速被细胞吸收。我们计划改变它的化学结构,使细胞或细菌更容易吸收它,特别是通过将氨基酸附着在ALA上,以帮助细胞吸收它。进入细胞后,药物会分解释放ALA。如果修饰的ALA药物可以更容易地进入细胞,那么原则上它应该对肿瘤治疗更有效,并且由于氨基酸是构成蛋白质的天然化合物,因此这些新药应该可以安全使用。除了治疗癌症外,还有几种类型的细菌甚至真菌感染可以使用PDT治疗。PDT用于治疗细菌的一个优点是可以治疗对抗生素具有抗性的细菌。例如,烧伤伤口经常被感染,在这种情况下,PDT药物可以应用于伤口,然后在药物渗透感染区域后进行照射。如果新型ALA药物可以更有效地被细菌吸收,那么PDT治疗应该更有效。我们还希望设计出经过修饰的ALA药物,这些药物通过附着氨基酸而被细菌特异性地分解,而不是被健康细胞分解,这些氨基酸的结构是通常天然存在的氨基酸的镜像。
英文摘要
The main aim of this project is to design new drugs for photodynamic therapy (PDT) which is a treatment that can be used for destroying cancers and killing infectious bacteria. The key feature feature of PDT is that it uses a light-activated drug known as a 'photosensitiser'. When light activates the drug this results in a toxic effect to tumour cells or bacteria leading to destruction of the tumour or healing of the bacterial infection. In effect, the light 'switches on' the drug but only in areas exposed to light. We propose to look at a new type of drug based on 5-aminolaevulinic acid (ALA). This is a natural compound present in many cells but normally at very low levels. However if cells or bacteria are exposed to high concentrations of ALA then a photosensitiser is produced (a porphyrin) which absorbs light over a wide range from red to blue and can therefore be used for PDT treatment. For example, a skin tumour can be treated by first covering the tumour with a lotion containing the ALA which is then left for a few hours. After ALA has seeped into the tumour, light is shone onto it for a few minutes to kill the tumour cells. Alternatively, a solution of ALA can be injected or given orally for the treatment of tumours inside the body where an endoscope can be used to guide the light onto the tumour. One main problem with using ALA however is that it is not quickly taken up by cells. We plan to change its chemical structure so that cells or bacteria can absorb it more easily, specifically by attaching amino acids to the ALA to help its uptake by cells. After entering the cell the drug would break down to release the ALA. If the modified ALA drug can enter cells more easily then in principle it should be more effective for tumour treatment, and since amino acids are natural compounds which make up proteins these new drugs should be safe to use. As well as treating cancers, there are several types of bacterial or even fungal infection which can be treated using PDT. One advantage of PDT for treating bacteria is that bacteria resistant to antibiotics can be treated. For example, burn wounds often become infected and in this case the PDT drug can be applied to the wounds and then illuminated after the drug has penetrated the infected area. If the new types of ALA drug can be taken up more efficiently by the bacteria then again the PDT treatment should be more effective. We also hope to design modified ALA drugs that are broken down specifically by bacteria and not by healthy cells by attaching amino acids whose structures are the mirror image of those which are normally found naturally.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/sj.bjc.6604928
发表时间:
2009-03-10
期刊:
BRITISH JOURNAL OF CANCER
影响因子:
8.8
作者:
[Bourre, L., Giuntini, F., Eggleston, I. M., Wilson, M., MacRobert, A. J.]
通讯作者:
MacRobert, A. J.
DOI:
10.1016/j.jconrel.2011.08.025
发表时间:
2012-01-30
期刊:
JOURNAL OF CONTROLLED RELEASE
影响因子:
10.8
作者:
[Wang, Julie T. -W., Giuntini, Francesca, MacRobert, Alexander J.]
通讯作者:
MacRobert, Alexander J.
Quantitative determination of 5-aminolaevulinic acid and its esters in cell lysates by HPLC-fluorescence.
通过 HPLC-荧光定量测定细胞裂解物中的 5-氨基乙酰丙酸及其酯。
DOI:
10.1016/j.jchromb.2008.09.031
发表时间:
2008
期刊:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
影响因子:
--
作者:
[Giuntini F]
通讯作者:
Giuntini F
Peptide-based solutions for light-triggered delivery of macromolecular therapeutics and nanoparticles
-
批准号:BB/J009318/1
-
项目类别:Research Grant
-
资助金额:$40.05万
-
财政年份:2012
-
负责人:Alexander MacRobert
-
依托单位:
Synthesis and biological studies of multifunctional dendritic conjugates of synergistically acting therapeutic agents
-
批准号:EP/G004382/1
-
项目类别:Research Grant
-
资助金额:$23.74万
-
财政年份:2008
-
负责人:Alexander MacRobert
-
依托单位:
国内基金
海外基金
登录
查看更多内容
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
-
批准号:82371102
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:苏蕴
-
依托单位:
应用RNA-only delivery基因回路靶向治疗CMS2型结肠癌的研究
-
批准号:82003254
-
项目类别:青年科学基金项目
-
资助金额:16.0万元
-
批准年份:2020
-
负责人:杨炯
-
依托单位:
内容分发网络中的P2P分群分发技术研究
-
批准号:61100238
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:郑小盈
-
依托单位:
聚乙二醇修饰的树状分子聚合物纳米基因载体在单基因缺陷所致的高脂血症的基因治疗研究中的应用
-
批准号:30971241
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:祁荣
-
依托单位:
基于生命节律的数字化口服给药系统及方法的研究
-
批准号:30700160
-
项目类别:青年科学基金项目
-
资助金额:16.0万元
-
批准年份:2007
-
负责人:皮喜田
-
依托单位:
供应链中生产和配送联合排序和调度的模型、算法及应用
-
批准号:70372058
-
项目类别:面上项目
-
资助金额:14.0万元
-
批准年份:2003
-
负责人:万国华
-
依托单位: